Selmaj, Krzysztof

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine

Multiple Sclerosis Research StudiesPsoriasis: Treatment and Pathogenesis

Cited by 2,021

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 1,905

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 1,205

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 1,198

Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity

Roxburgh, R. H. S. R., Seaman, S. R., Masterman, T., Hensiek, A. E., Sawcer, S. J., Vukusic, S., Achiti, I., Confavreux, C., Coustans, M., le Page, E., et al. (2005) · Neurology

Multiple Sclerosis Research StudiesHealth Systems, Economic Evaluations, Quality of Life

Cited by 963

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet

Multiple Sclerosis Research StudiesSphingolipid Metabolism and Signaling

Cited by 942

Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin

Selmaj, K., Raine, C. S., Farooq, M., Norton, W. T., & Brosnan, C. F. (1991) · The Journal of Immunology

Cell death mechanisms and regulationNeuroinflammation and Neurodegeneration Mechanisms

Cited by 451

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H.-P., Havrdova, E., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 277

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H.-P., Fox, E. J., Giovannoni, G., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 221

miR-155-3p Drives the Development of Autoimmune Demyelination by Regulation of Heat Shock Protein 40

Mycko, M. P., Cichalewska, M., Cwiklinska, H., & Selmaj, K. W. (2015) · The Journal of Neuroscience

Multiple Sclerosis Research StudiesMicroRNA in disease regulation

Cited by 88

TNF‐induced death of adult human oligodendrocytes is mediated by c‐jun NH2‐terminal kinase‐3

Jurewicz, A., Matysiak, M., Tybor, K., & Selmaj, K. (2003) · Brain

Cell death mechanisms and regulationMultiple Sclerosis Research Studies

Cited by 70